| ||||||||||||||
|
|
|||||||||||||
Klinik für Anaesthesiologie, Technische Universität München, München, Germany
Address correspondence and reprint requests to Sabine Himmelseher, Klinik für Anaesthesiologie, Klinikum rechts der Isar, Technische Universität München, Ismaningerstr. 22, D-81675 München, Germany. Address e-mail to S.Himmelseher{at}lrz.tu-muenchen.de
| Abstract |
|---|
|
|
|---|
Implications: Epidural S(+)-ketamine applied with ropivacaine before surgery is a rational approach to decrease injury-induced pain sensitization. Epidural blockade with an N-methyl-D-aspartate receptor antagonist and a local anesthetic may provide better analgesia in the postoperative period than a local anesthetic alone.
| Introduction |
|---|
|
|
|---|
Racemic ketamine blocks NMDA receptor activation in a noncompetitive manner (4,5). In pain-preventive regimens, subanesthetic-dose IV ketamine reduced postoperative pain (6,7), and in combination with epidural opioids or local anesthetics, epidural ketamine increased postoperative analgesia (810). S(+)-ketamine, the left-handed optical isomer of racemic ketamine, has a fourfold higher affinity for NMDA receptors than right-handed R(-)-ketamine (5,11). Investigative trials indicate that this difference results in a clinical analgesic potency of S(+)-ketamine that is two times higher in comparison with racemic ketamine (12,13). S(+)-ketamine is now available in some European countries, and a preservative-free formulation that may be administered into the epidural space has been introduced.
Because epidural anesthesia and postoperative epidural analgesia have been associated with accelerated rehabilitation after knee arthroplasty (1), we compared the efficacy of postoperative patient-controlled epidural analgesia (PCEA) by using ropivacaine after epidural anesthesia with ropivacaine compared with that with S(+)-ketamine and ropivacaine.
| Methods |
|---|
|
|
|---|
On the preoperative visit, patients were made familiar with the visual analog scale (VAS), which ranged from 0 = no pain to 10 = worst pain imaginable. Use of the PCEA device (Graseby Medical Ltd., Watford, UK) was explained.
On the day of surgery, patients were premedicated with oral midazolam (3.757.5 mg) 1 h before surgery. In the operation room, an IV infusion was established, and prehydration with at least 500 mL lactated Ringers solution was provided. An epidural catheter was preferentially inserted at the L3-4 interspace, but variations in the site of insertion were allowed from T12 through L4. The epidural space was identified by loss of resistance. The catheter was advanced 35 cm, and a 4-mL test dose of ropivacaine (10 mg/mL) (Astra Chemicals, Wedel, Germany) eliminated subarachnoid insertion. Five minutes after a negative response, 1015 mL epidural ropivacaine was titrated in aliquots of 5 mL to a sensory block of at least dermatome T12. If adequate sensory block was not achieved within 45 min, an additional 5-mL dose of ropivacaine was injected. A limit of a maximum dose of 250 mg ropivacaine within a 3-h interval was set. For patient comfort, light sedation with IV propofol or midazolam was provided. Sensory block was confirmed before surgery was started.
According to a computer-generated table of random numbers, patients were allocated to receive either 0.25 mg/kg epidural S(+)-ketamine (Parke-Davis Pharmaceuticals, Freiburg, Germany) or an equivalent volume of epidural 0.9% saline 10 min before surgical incision. The S(+)-ketamine dose chosen was based on open-label pilot studies in the same setting. We studied the effects of 0.125, 0.25, 0.5, and 0.75 mg/kg epidural S(+)-ketamine, and we observed increased postoperative pain relief and a 15%40% decrease in ropivacaine demand after 0.25 mg/kg S(+)-ketamine. The smaller doses assessed resulted in negligible effects, whereas the larger doses studied caused increased patient sedation. Therefore, 0.25 mg/kg S(+)-ketamine was used for the investigation. Only commercially available preservative-free S(+)-ketamine was applied. Patients and investigator anesthetists were blinded as to patient group allocation.
On completion of surgery, analgesic therapy was commenced. The PCEA device was programmed to administer a bolus dose of 18.75 mg (5 mL) of ropivacaine (3.75 mg/mL) with a 10-min lockout and a maximum dose limit of 200 mg of ropivacaine over 4 h. Postoperative evaluations were performed at 2-h intervals for the first 8 h after surgery and then at 24 and 48 h after surgery. VAS scores at rest and during movement and PCEA consumption of ropivacaine were recorded. The time until first analgesic medication request was noted. Sensation to touch (with the scale 0 = none, 1 = pinprick, 2 = touch, to 3 = correct identification of a number written on the skin) was determined on the skin surrounding the operated area and the corresponding region on the contralateral extremity. Motor block was assessed bilaterally according to a modified Bromage scale (0 = no motor block, 1 = ability to move knee and ankle, 2 = ability to move ankle, 3 = inability to move ankle).
A standardized plan for postoperative rescue analgesia was prepared. If VAS scores were higher than 4 cm, nonsteroidal antiinflammatory drugs (50100 mg diclofenac or 0.51 g paracetamol administered per rectum or orally) were first used, followed by the nonopioid analgesic metamizol (12 g IV). In case of pain persistence after 45 min, subcutaneous injections of piritramide (1.5 up to 7.5 mg) were provided. If the VAS scores were higher than 5 cm, piritramide was administered IV. If analgesia was not achieved with these treatments, the PCEA was discontinued, and 510 mL (18.7537.5 mg) boluses of ropivacaine could be epidurally applied at the discretion of the anesthetist. If, after 45 min, pain control was considered inadequate (VAS scores higher than 4 cm), a continuous infusion of 0.2% epidural ropivacaine was provided. Finally, an IV patient-controlled analgesia device with piritramide could be set up.
Adverse events were noted. Special attention was paid to all side effects that could be associated with ketamine (510). Patients were questioned about unusual dreams, hallucinations, or other psychological effects possibly related to ketamine. Noninvasive blood pressure and heart rate were monitored, and the state of sedation was assessed (4-point score: 0 = no sedation, 1 = mild sedation, 2 = moderate sedation, 3 = severe sedation) at 30-min intervals. Patients ratings of the quality of their overall pain therapy were recorded at 48 h with a 4-point scale of 1 = poor, 2 = fair, 3 = good, or 4 = excellent.
Calculations from the pilot studies showed that 15 patients per group would allow detection of a difference of 20% in postoperative ropivacaine consumption with an overall
error at the 0.05 level and an 80% power. All P values were two sided. Where appropriate, results are presented as count and were statistically compared between groups by contingency table analysis. Continuous variables are reported as mean ± SD or median and range (25th75th percentile) when data were not normally distributed. Discrete results are expressed as median and range (25th75th percentiles). Nonparametric data were analyzed with the Kruskal-Wallis test combined with Dunns test for intergroup comparison. Parametric data were compared between groups by analysis of variance and post hoc testing with Dunnetts test. Analysis was performed with the Statistical Package for the Social Sciences (SPSS, Inc., Chicago, IL) and StatView 4.5 (Abacus Concepts, Berkeley, CA).
| Results |
|---|
|
|
|---|
|
|
|
|
| Discussion |
|---|
|
|
|---|
Total knee arthroplasty is associated with a frequent incidence of intense postoperative pain, especially during early attempts of mobilization (1). Our analysis focused on the first 48 hours after surgery, during which many patients experience a peak pain level. We chose to compare postoperative analgesia with epidural ropivacaine after epidural anesthesia with S(+)-ketamine and ropivacaine versus ropivacaine. Epidural anesthesia with local anesthetics is often used for knee arthroplasty, and studies with epidural ropivacaine indicate safe and effective analgesia with minimal side effects after major orthopedic surgery (14).
Concern has been expressed about neurotoxicity after neuraxial use of ketamine, because spinal myelopathy has been reported with intrathecal injection of large doses (15). However, in animals and humans, there is no evidence for neurological injury after repeated intrathecal injection of preservative-free ketamine (16,17). Little is known about the pharmacokinetic distribution of epidural ketamine. In a dog model, racemic ketamine was rapidly absorbed from the epidural space into the cerebrospinal fluid and plasma with a longer plasma half-life than if applied IV (18). In humans, a single five-milligram epidural injection gained rapid access to the systemic circulation with 80% bioavailability (19). One possible criticism of this study is therefore the lack of blood measurements of S(+)-ketamine and its metabolites. Thus we cannot comment on systemic analgesic effects possibly induced by epidural S(+)-ketamine. A limitation of our investigation may be the lack of a patient group receiving an equipotent dose of racemic ketamine relative to S(+)-ketamine. Ethical considerations dominated our decision not to investigate such a group, because epidural small-dose racemic ketamine combined with bupivacaine failed to improve postoperative pain relief after knee arthroplasty with epidural anesthesia in a study by Weir and Fee (20).
The postoperative VAS scores obtained after ropivacaine in this investigation compare with VAS scores for unilateral knee arthroplasty with epidural anesthesia and postoperative epidural analgesia that have been reported in the literature (1,9,14). The few trials available that studied preoperative use of epidural racemic ketamine, however, cannot be directly compared with our study. Choe et al. (8) found that patients receiving anesthetic-dose ketamine and morphine before the incision versus at the end of gastrectomy during general anesthesia had longer lasting postoperative pain control and reduced analgesic demand after 48 hours. Wong et al. (9) observed decreased opioid consumption and lower VAS pain scores over three days when patients received preoperative small-dose ketamine, morphine, and lidocaine compared with use at 30 minutes after the start of knee arthroplasty with epidural anesthesia or with general anesthesia and postincisional ketamine. Abdel-Ghaffar et al. (10) reported a prolonged time interval to first postoperative analgesic request and a reduced 24-hour analgesic demand when preoperative small-dose ketamine was used for hysterectomy with general anesthesia.
Activation of NMDA receptors within the spinal cord is thought to be central to the genesis of acute and chronic pain (2,3). Surgically induced tissue-damaging injury sustains altered processing of afferent noxious input and pain hypersensitivity acting in part through NMDA receptor activation (2,3). The most persuasive mechanism that underlies the analgesic action of subanesthetic-dose ketamine is related to NMDA-receptor blockade (4,5). Ketamine may inhibit a facilitated state of excitability by suppressing a progressive increase in nociceptive responses caused by wind-up phenomenon, long-term potentiation, and summation pain (2,12,13). Once pain sensitization from incisional and inflammatory injury is established, ketamine reduces NMDA receptor-related altered pain transmission and thus hyperalgesia (12,13,21). This explains in part why a study comparing preoperative epidural anesthetic-dose ketamine with the same dose applied before wound closure failed to show a difference in analgesia after abdominal surgery with general anesthesia (22). One further explanation for the increased pain relief in our study is the potential complementary antinociceptive action of the two drug classes used. Local anesthetics do not block all pain-sensitizing mechanisms (23,24), and intrathecal ketamine does not completely abolish hyperalgesia when used alone (21).
The difference in pain between groups did not emerge until 24 hours after surgery. This period may reflect the interval required for the sensitizing effects of surgery to become established, or it may reflect the overwhelming contribution of peripheral inputs from the operated knee, which obscured the spinal component of nociception in the earlier postsurgical period. Sustained injury causes several periods of enhanced spinal activity (2,3,21). In particular, there appears to be a crucial time interval during the first minutes to hours after surgery, and there is a second phase of inflammatory injury that depends on the first period (2,3,21). Clearly, the delayed onset of pain relief after S(+)-ketamine is not likely to be the result of direct analgesic effects, because it greatly exceeds the pharmacologic duration of a single epidural drug injection (19). Nevertheless, because we did not compare preincisional S(+)-ketamine with the administration of postincisional S(+)-ketamine, we cannot decisively state that preemptive analgesia was proved. We can only speculate that S(+)-ketamine blocked pain sensitization during the entire observation period but that its antinociceptive effects were on the one hand clouded by the effects of ropivacaine during the first postoperative hours, and on the other hand did not become clinically manifest before patient mobilization was started. In addition, there is evidence that the binding of noncompetitive NMDA receptor antagonists occurs relatively slowly, and this may contribute to the delayed analgesic effects we found (25). Conceptually, repeated use of S(+)-ketamine could enhance the pain reduction observed. This should be addressed in the future.
Use of S(+)-ketamine in our awake patients was not associated with an increase in adverse events or the occurrence of unpleasant psychological effects. This may be because the patients were premedicated with a benzodiazepine or because a small drug dose was applied.
The patients treated with S(+)-ketamine rated the quality of their pain therapy better. Patient perception of wellness should influence the choice of analgesics for postoperative pain management. In our opinion, increased patient satisfaction justifies the adjunctive use of small-dose S(+)-ketamine, given the ease of implementation and small cost of this new regimen.
In summary, we suggest that the use of a small dose of epidural S(+)-ketamine with a local anesthetic before surgical injury may decrease injury-induced pain sensitization and therefore provide better analgesia in the postoperative period than that achieved with a dose of local anesthetic alone in the epidural space.
| Acknowledgments |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. S. Reuben and A. Buvanendran Preventing the Development of Chronic Pain After Orthopaedic Surgery with Preventive Multimodal Analgesic Techniques J. Bone Joint Surg. Am., June 1, 2007; 89(6): 1343 - 1358. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. F. White The Changing Role of Non-Opioid Analgesic Techniques in the Management of Postoperative Pain Anesth. Analg., November 1, 2005; 101(5S_Suppl): S5 - 22. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Lahtinen, H. Kokki, T. Hakala, and M. Hynynen S(+)-Ketamine as an Analgesic Adjunct Reduces Opioid Consumption After Cardiac Surgery Anesth. Analg., November 1, 2004; 99(5): 1295 - 1301. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. L. McCartney, A. Sinha, and J. Katz A Qualitative Systematic Review of the Role of N-Methyl-D-Aspartate Receptor Antagonists in Preventive Analgesia Anesth. Analg., May 1, 2004; 98(5): 1385 - 1400. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-T. Liou, J.-C. Hsu, F.-C. Liu, D. Ching-Wah Sum, and P.-W. Lui Pretreatment with Small-Dose Ketamine Reduces Withdrawal Movements Associated with Injection of Rocuronium in Pediatric Patients Anesth. Analg., November 1, 2003; 97(5): 1294 - 1297. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Haeseler, D. Tetzlaff, J. Bufler, R. Dengler, S. Munte, H. Hecker, and M. Leuwer Blockade of Voltage-Operated Neuronal and Skeletal Muscle Sodium Channels by S(+)- and R(-)-Ketamine Anesth. Analg., April 1, 2003; 96(4): 1019 - 1026. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Schmid, G. Koren, J. Klein, and J. Katz The Stability of a Ketamine-Morphine Solution Anesth. Analg., April 1, 2002; 94(4): 898 - 900. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|